Latest:
Dr. Jamieson on Treatment Considerations in Myelofibrosis
Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.
Authors
Núria Agustí, MD
Núria Agustí, MD, is a postdoctoral fellow at MD Anderson Cancer Center in Houston, Texas.
Latest:
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Núria Agustí, MD, discusses patient eligibility in a cohort study assessing adjuvant chemoradiotherapy vs radiotherapy alone in patients with cervical cancer.
Pedro C. Barata, MD, MSc, FACP
Latest:
Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.
Chunyan Lan, MD, PhD
Chunyan Lan, MD, PhD, is from the Department of Gynecologic Oncology at Sun Yat-sen University Cancer Center
Latest:
Dr Lan on the Efficacy of Cadonilimab Plus Lenvatinib in Advanced Endometrial Cancer
Chunyan Lan, MD, PhD, discusses data with cadonilimab plus lenvatinib in advanced endometrial cancer, as well as next steps for evaluating the combination.
Monica H. Vetter, MD
Latest:
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer
Monica H. Vetter, MD, on the implications for inclusion criteria for insurance approvals for pembrolizumab- and dostarlimab-based regimens in endometrial cancer.
Rino S. Seedor, MD
Latest:
Dr. Seedor on Treatment Sequencing in Metastatic Melanoma
Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.